retatrutide dosage phase 2 trial Reta clinical data & dosing — a must read (Reta) isn't just another GLP-1. It's a triple-agonist peptide studied in 3 trials for metabolic health — targeting GLP-1, GIP ESC 2024: Retatrutide improves lipid

Research has also indicated that they can raise the risk of gastroesophageal reflux disease (GERD) and acid reflux, likely because they slow the emptying of food from the stomach

The future of obesity treatment is quality weight loss The next generation of obesity research is increasingly focused on more than total weight loss

The STEP 1 trial showed semaglutide 2.4 mg led to 14.9% weight loss over 68 weeks, while SURMOUNT-1 showed tirzepatide achieved up to 20.9% weight reductionapproaching bariatric surgery outcomes.[6] The SELECT trial (17,604 patients) found semaglutide reduced cardiovascular death, non-fatal heart attack, and non-fatal stroke by 20% and all-cause mortality by 19%, suggesting direct cardioprotective effects beyond weight loss.[4] In STEP-HFpEF, semaglutide produced 13.3% weight loss in heart failure patients and improved symptoms and physical function

Start your intake Understanding GLP-1 Semaglutide and Anticoagulant Compatibility Semaglutide belongs to a medication class called GLP-1 receptor agonists, which primarily work by slowing gastric emptying and increasing insulin secretion in response to meals